Logo
x

Search

Subscribe Now

osteoarthritis

Sorrento's Resiniferatoxin Receives the US FDA's Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with Osteoarthritis

Sorrento's Resiniferatoxin Receives the US FDA's Clearance to Initiate P-II Trial for the Treatment of Knee Pain in Patients with...

  • July 7, 2021
Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis

Merck Signs an Out-Licensing Agreement with Novartis for M6495 (Anti-ADAMTS5 Nanobody) for Osteoarthritis

  • October 7, 2020
Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthritis

Pfizer and Eli Lilly Report the US FDA Acceptance of BLA for Tanezumab to Treat Chronic Pain Due to Moderate-to-Severe Osteoarthri...

  • March 2, 2020
Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis

Pfizer & Eli Lilly Report Results of Tanezumab in Long-Term P-III Study for Osteoarthritis

  • April 19, 2019
Pfizer Reports Improved Results of P-III OA (A4091056) Study of Tanezumab in Patients with Osteoarthritis (OA)

Pfizer Reports Improved Results of P-III OA (A4091056) Study of Tanezumab in Patients with Osteoarthritis (OA)

  • October 25, 2018
FDA Reports Newly Added Guidelines for Drug and Device Makers

FDA Reports Newly Added Guidelines for Drug and Device Makers

  • August 31, 2018
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2024 PharmaShots - All Rights Reserved.